EUVIMEDOpdag EUVIMED
Open access

Racial–ethnic differences in liver transplant waitlist outcomes in patients with hepatocellular carcinoma before and after recent changes to allocation policy

Rafal D Mazur iD, David C Cron, David S Goldberg, Heidi Yeh, Leigh Anne Dageforde iD

Clinical Transplantation · 2024

DOI: 10.1111/ctr.15365 ↗

At a glance

Journal article in Clinical Transplantation, 2024. Written by Rafal D Mazur and 4 co-authors. Institution: Harvard Medical School, Boston, Massachusetts, USA. Major MEDLINE topics: Carcinoma, Hepatocellular, Ethnicity, Liver Neoplasms, Liver Transplantation. Cited 5 times so far (Crossref); 30 references. The full text is freely available in PubMed Central. Funded by: NIDDK NIH HHS, NIAAA NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

In May 2019, liver transplant (LT) allocation policy changed to limit MELD exception points for hepatocellular carcinoma (HCC) to median MELD at transplant minus three (MMaT‐3). We evaluated this policy's impact on waitlist outcomes for HCC candidates, by race and ethnicity, hypothesizing that the introduction of the MMaT‐3 reduced inequities in waitlist outcomes.

Methods

Retrospective cohort study of the Scientific Registry for Transplant Recipients, including all adult LT candidates ( N = 10 751) who received HCC exception points from May 17, 2017 to May 18, 2019 (pre‐policy; N = 6627) to May 19, 2019 to March 1, 2021 (post‐policy; N = 4124). We compared incidence of LT and waitlist removal for death or becoming too sick pre‐ and post‐policy for non‐Hispanic White, non‐Hispanic Black, Hispanic/Latinx, and Asian patients using competing risk regression adjusted for candidate characteristics.

Results

One‐year cumulative incidence of LT decreased significantly pre‐/post‐policy among White (77.4% vs. 64.5%; p < .01) and Black (76.2% vs. 63.1%; p < .01) candidates only, while a 1‐year incidence of death/non‐LT waitlist removal decreased significantly only among Hispanics (13.4% vs. 7.5%; p < .01). After covariate adjustment, the effect of the policy change was a significantly decreased incidence of LT for White (SHR: .63 compared to pre‐policy; p < .001), Black (SHR: .62; p < .001), and Asian (SHR: .68; p = .002), but no change for Hispanic patients. Only Hispanic patients had a significant decrease in death/waitlist removal after the policy change (SHR: .69; p = .04). Compared to White patients in the pre‐policy era, Hispanic (SHR: .88, p < .007) and Asian candidates (SHR: .72; p < .001) had lower unadjusted incidence of LT. This disparity was mitigated in the post‐policy era where Hispanic patients had higher likelihood of LT than Whites (SHR: 1.22; p = .002). For the outcome of death/non‐LT waitlist removal, the only significant difference was a 42% lower incidence of waitlist removal for Asian compared to White patients in the post‐policy era (SHR: .58; p = .03).

Conclusion

Among LT recipients with HCC, racial/ethnic subpopulations were differentially affected by the MMAT‐3 policy, resulting in a post‐policy reduction of some of the previous disparities.

Subjects

MeSH terms (MEDLINE)

Carcinoma, HepatocellularEthnicityLiver NeoplasmsLiver TransplantationTissue and Organ ProcurementWaiting ListsAdultAgedFemaleHumansMaleMiddle AgedFollow-Up StudiesHealthcare DisparitiesPrognosisRacial GroupsRegistriesRetrospective StudiesSurvival RateBlack or African AmericanHispanic or LatinoAsianWhite

Author keywords

ethnicityhepatocellular carcinomaliver transplantationracewaitlist outcomes

Authors and institutions

  • Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Division of Digestive Health and Liver Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.
  • Division of Transplantation, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA.

ORCID profiles: Rafal D Mazur, Leigh Anne Dageforde

Funding

  • NIDDK NIH HHS
  • NIAAA NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • NIAID NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institute on Alcohol Abuse and Alcoholism

Cite

APA

Mazur, R. D., Cron, D. C., Goldberg, D. S., Yeh, H., & Dageforde, L. A. (2024). Racial–ethnic differences in liver transplant waitlist outcomes in patients with hepatocellular carcinoma before and after recent changes to allocation policy. Clinical Transplantation. https://doi.org/10.1111/ctr.15365

Vancouver

Mazur RD, Cron DC, Goldberg DS, Yeh H, Dageforde LA. Racial–ethnic differences in liver transplant waitlist outcomes in patients with hepatocellular carcinoma before and after recent changes to allocation policy. Clinical Transplantation. 2024. doi:10.1111/ctr.15365

BibTeX
@article{Mazur2024,
  author = {Mazur, Rafal D and Cron, David C and Goldberg, David S and Yeh, Heidi and Dageforde, Leigh Anne},
  title = {Racial–ethnic differences in liver transplant waitlist outcomes in patients with hepatocellular carcinoma before and after recent changes to allocation policy},
  journal = {Clinical Transplantation},
  year = {2024},
  doi = {10.1111/ctr.15365}
}
Start for free →